Our Clinical Pipeline

mKRAS for Asian

Equipped with unfound KRAS mutant antigens, we are developing an industry-leading clinical trial for Asian patients. Partner with us to develop the best-in-class clinical solution using multiple antigens derived from our proprietary PiperT workflow.

Coming soon

Coming Soon